. Author manuscript; available in PMC: 2019 Mar 27.

Published in final edited form as: Acta Oncol. 2009;48(7):955–963. doi: 10.1080/02841860903104145

Table II.

Case-control studies on polymorphisms of interleukins (IL) and focal epilepsy.

First Author	Specific polymorphism	Epilepsy type	Nr of patients and controls	Outcome statistics and p-value
Kanemoto [33]	IL- 1β- 511	TLE-HS+	50 cases and 112 controls	χ²=9.55 p<0.017
Kanemoto [34]	IL- 1β- 511	TLE-HS+ and PFC	66 cases, 133 controls	TLE-HS+: χ²=9.38 p=0.0022
Kanemoto [34]	IL- 1β- 511	TLE-HS+ and PFC		PFC: χ²=9.90 P=0.0016
Ozkara [35]	IL-1β-511; IL-1β+3953; IL-1α-889	TLE-HS+	47 cases, 99 controls	NS
Heils [36]	IL-1β-511		86 cases, 133 controls	χ²=0.436 p=0.804
Buono [37]	IL-1β −511	TLE-HS+	61 cases, 119 controls	χ²=5.22 p=0.09
Jin [38]	IL-1β- 511	TLE-HS+ and TLE-HS−	112 cases, 115 controls	NS

TLE: temporal lobe epilepsy.

TLE-HS+: temporal lobe epilepsy with hippocampal sclerosis.

TLE-HS−: temporal lobe epilepsy without hippocampal sclerosis.

PFC: prolonged febrile convulsions.